April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Efficacy and Safety of Intravitreal Bevacizumab in Eyes With Neovascular Glaucoma Undergoing Ahmed Glaucoma Valve Implantation - Preliminary Report
Author Affiliations & Notes
  • E. S. Arcieri
    Ophthalmology, University of Campinas, Campinas, Brazil
    Ophthalmology, Federal University of Uberlandia, Uberlandia, Brazil
  • D. J. L. Secches
    Ophthalmology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
  • J. S. Paula
    Ophthalmology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
  • K. A. Barella
    Ophthalmology, University of Campinas, Campinas, Brazil
  • R. S. Arcieri
    Ophthalmology, Hospital Ana Costa, Santos, Brazil
  • R. Jorge
    Ophthalmology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil
  • V. P. Costa
    Ophthalmology, University of Campinas, Campinas, Brazil
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  E.S. Arcieri, None; D.J.L. Secches, None; J.S. Paula, None; K.A. Barella, None; R.S. Arcieri, None; R. Jorge, None; V.P. Costa, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 627. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. S. Arcieri, D. J. L. Secches, J. S. Paula, K. A. Barella, R. S. Arcieri, R. Jorge, V. P. Costa; Efficacy and Safety of Intravitreal Bevacizumab in Eyes With Neovascular Glaucoma Undergoing Ahmed Glaucoma Valve Implantation - Preliminary Report. Invest. Ophthalmol. Vis. Sci. 2010;51(13):627.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed Glaucoma Valve implantation.

Methods: : Multicenter, prospective, randomized clinical trial that enrolled 29 patients from 3 centers. All patients with uncontrolled neovascular glaucoma that had undergone panretinal photocoagulation and required glaucoma drainage device implantation were eligible. Patients were randomized to receive intravitreal injections of bevacizumab (1.25mg) or not during Ahmed Valve implant surgery. Injections were performed intraoperatively, and 4 and 8 weeks after surgery.

Results: : The preoperative data were similar between groups. After a mean follow-up of 7.96 ± 3.95 months, both groups showed a similar decrease in IOP (50.7% in the bevacizumab group and 61.5% in the control group, p=0.7750). Postoperatively, there were no significant differences in visual acuity (p>0.1270), mean number of antiglaucoma medications (p>0.3112), and extension of goniosynechiae (p>0.0685) between the groups. At the end of follow-up, the decrease in the extension of new vessels in the anterior chamber angle in the bevacizumab group was significantly higher than in the control group (p=0.0051). Although both groups showed a significant decrease in the extension of rubeosis iridis at the end of follow-up (p<0.05), complete regression of rubeosis iridis was significantly more frequent in the bevacizumab group (92.3%) than in the control group (25%) (p=0.0011).

Conclusions: : Bevacizumab may lead to regression of new vessels both in the iris and the anterior chamber angle in patients with neovascular glaucoma undergoing Ahmed Glaucoma Valve implantation. Nevertheless, these findings were not associated with better IOP control after a short term follow-up.

Clinical Trial: : www.anzctr.org.au ACTRN12607000577415

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • iris • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×